<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03855384</url>
  </required_header>
  <id_info>
    <org_study_id>TQB2450-II-03</org_study_id>
    <nct_id>NCT03855384</nct_id>
  </id_info>
  <brief_title>Study of TQB2450 in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck（R/M SCCHN）</brief_title>
  <official_title>Multicenter, Randomized, Double-blind, Phase Ⅲ Clinical Study to Evaluate the Efficacy and Safety of TQB2450 Plus Chemotherapy（Cisplatin or Carboplatin+ 5-Fluorouracil (5-FU) ） Versus Placebo Plus Chemotherapy as First-Line Treatment in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma（R/M SCCHN）</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which&#xD;
      prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell&#xD;
      activity, thus enhancing immune response and has potential to treat various types of tumors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">June 11, 2019</start_date>
  <completion_date type="Anticipated">May 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>OS</measure>
    <time_frame>up to 72 weeks</time_frame>
    <description>Overall survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>DOR</measure>
    <time_frame>up to 72 weeks</time_frame>
    <description>Duration of Response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>Progression-free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>Disease Control Rate</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">334</enrollment>
  <condition>Squamous Cell Carcinoma of the Head and Neck</condition>
  <arm_group>
    <arm_group_label>TQB2450+cisplatin or carboplatin + 5-Fluorouracil (5-FU)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo+cisplatin or carboplatin + 5-Fluorouracil (5-FU)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TQB2450+cisplatin or carboplatin + 5-Fluorouracil (5-FU)</intervention_name>
    <description>TQB2450 1200mg IV ，cisplatin 75 mg/m^2 IV or carboplatin AUC 5 IV on Day 1 of each week in 3-week cycles (6 cycle maximum); plus 5-FU 750 mg/m^2/day IV continuous from Day 1-5 of each 3- week cycle (6 cycle maximum).</description>
    <arm_group_label>TQB2450+cisplatin or carboplatin + 5-Fluorouracil (5-FU)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo+cisplatin or carboplatin + 5-Fluorouracil (5-FU)</intervention_name>
    <description>placebo 1200mg IV ，cisplatin 75 mg/m^2 IV or carboplatin AUC 5 IV on Day 1 of each week in 3-week cycles (6 cycle maximum); plus 5-FU 750 mg/m^2/day IV continuous from Day 1-5 of each 3- week cycle (6 cycle maximum).</description>
    <arm_group_label>placebo+cisplatin or carboplatin + 5-Fluorouracil (5-FU)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically or cytologically confirmed head and neck squamous cell carcinoma&#xD;
             ，primary tumor locations of oropharynx, oral cavity, hypopharynx, or larynx.&#xD;
&#xD;
          2. No indications of local radical therapy for recurrence/metastasis head and neck&#xD;
             squamous cell carcinoma.&#xD;
&#xD;
          3. At least one measurable lesion（ based on RECIST1.1）.&#xD;
&#xD;
          4. Can provide tissue for PD-L1 biomarker analysis: A newly obtained biopsy is preferred&#xD;
             but an archival sample is acceptable.&#xD;
&#xD;
          5. Tumors express PD-L1,and PD-L1 expression on at least 1% of tumour cells .&#xD;
&#xD;
          6. 18 years and older.&#xD;
&#xD;
          7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.&#xD;
&#xD;
          8. Life expectancy of at least 3 months.&#xD;
&#xD;
          9. The main organs function are normally, the following criteria are met:&#xD;
&#xD;
               1. routine blood tests：hemoglobin（Hb）≥90g/L（no blood transfusion and blood products&#xD;
                  within 14 days）；absolute neutrophil count（ANC）≥1.5×109/L；&#xD;
                  platelets（PLT）≥100×109/L.&#xD;
&#xD;
               2. Blood biochemical examination: alanine transaminase（ALT）and aspartate&#xD;
                  aminotransferase（AST）≤2.5×upper limit of normal (ULN)（when the liver is invaded,&#xD;
                  ALT, and AST ≤5× upper limit of normal (ULN) ）； total bilirubin (TBIL)≤1.5×upper&#xD;
                  limit of normal (ULN)（Gilbert syndrome patients，≤3×upper limit of normal (ULN)）；&#xD;
                  calculated creatinine clearance（CrCl）≥60mL/min（Creatinine clearance criteria for&#xD;
                  subjects treated with cisplatin）or CrCl≥50mL/min（Creatinine clearance criteria&#xD;
                  for subjects treated with carboplatin）(Application of Standard Cockcroft-Gault&#xD;
                  Formula).&#xD;
&#xD;
               3. Coagulation function: activated partial thromboplastin time (aPTT) 、&#xD;
                  international normalized ratio (INR) 、prothrombin time（PT）≤ 1.5×upper limit of&#xD;
                  normal (ULN).&#xD;
&#xD;
               4. left ventricular ejection fraction (LVEF) measured by the Cardiac&#xD;
                  echocardiography greater than or equal to 50%.&#xD;
&#xD;
         10. Male or female subjects should agree to use an adequate method of contraception&#xD;
             starting with the first dose of study therapy through 6 months after the last dose of&#xD;
             study(Such as intrauterine devices , birth control pills or condoms) ；Not Pregnant or&#xD;
             breastfeeding women,Pregnancy before pregnancy screening（Within 7 days before the&#xD;
             start of the study）, the women who blood / urine results were positive.&#xD;
&#xD;
         11. Understood and signed an informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Received systemic chemotherapy, but not chemotherapy for locally advanced disease as&#xD;
             part of multimodality therapy (this treatment must be completed more than 6 months&#xD;
             after informed consent).&#xD;
&#xD;
          2. Has progressive disease (PD) within six (6) months of completion of curatively&#xD;
             intended systemic treatment for locoregionally advanced HNSCC.&#xD;
&#xD;
          3. Prior therapy with an anti-programmed cell death (PD)-1, anti-PD-L1, anti-PD-L2,&#xD;
             anti-tumor necrosis factor CD137, or anti-cytotoxic T-lymphocyte-associated antigen-4&#xD;
             (CTLA-4) antibody ,or any other antibody or drug specifically targeting T-cell&#xD;
             co-stimulation or checkpoint pathways.&#xD;
&#xD;
          4. Patients who have received cetuximab treatment within 6 moths before randomization.&#xD;
&#xD;
          5. Diagnosed and/or treated additional malignancy within 5 years prior to randomization&#xD;
             with the exception of cured carcinoma in situ of the cervix、intramucosal carcinoma of&#xD;
             gastrointestinal tract、breast and non-melanoma skin cancers and superficial bladder&#xD;
             tumors.&#xD;
&#xD;
          6. Known untreated central nervous system (CNS) metastasis and/or carcinomatous&#xD;
             meningitis. 7. Has neuropathy that is ≥ Grade 2 by Common Terminology Criteria for&#xD;
             Adverse Events (CTCAE) version 5 criteria.&#xD;
&#xD;
        8. Previously had a severe hypersensitivity reaction to treatment with study drug or has a&#xD;
        known sensitivity to any component of drug , including Severe hypersensitivity reaction≥3&#xD;
        grades (NCI CTCAEv5.0 )to monoclonal antibody 、fluorouracil、 carboplatin or&#xD;
        cisplatin-related compounds.&#xD;
&#xD;
        9. Active autoimmune disease that may worsen with the administration of an immunostimulant.&#xD;
        Patients with type 1 diabetes, vitiligo, psoriasis, or hypothyroidism or hyperthyroidism&#xD;
        that do not require immunosuppression therapy are excluded.&#xD;
&#xD;
        10. Immunosuppressive drugs were used at randomization,except that:&#xD;
&#xD;
          1. Intranasal, inhaled, topical steroid or topical steroid injection (e.g.&#xD;
             intra-articular injection)&#xD;
&#xD;
          2. Physiological doses of systemic corticosteroids (a dose of ≤ 10 mg daily prednisone&#xD;
             (or equivalent) )&#xD;
&#xD;
          3. Preadministration of steroids for hypersensitivity reactions (e.g., preadministration&#xD;
             of CT scans)&quot; 11. Interstitial lung disease or non-contagious pneumonia (including&#xD;
             past history and current illness); uncontrolled systemic diseases including diabetes,&#xD;
             hypertension,acute lung disease, etc. except for radiotherapy-induced interstitial&#xD;
             pneumonitis.&#xD;
&#xD;
             12. Has any other active infection requiring systemic therapy,including patients with&#xD;
             active tuberculosis.&#xD;
&#xD;
             13. Unstable pleural effusion, pericardial effusion or ascites. 14. Significant&#xD;
             cardiovascular diseases such as heart failure of New York Heart Academy(NYHA) Class 2&#xD;
             and above, myocardial infarction within the past 3 months, unstable arrhythmias&#xD;
             (including QT interval ≥480 ms) or unstable Angina.&#xD;
&#xD;
             15. Patients with immunodeficiency, including HIV positive or other acquired,&#xD;
             congenital immunodeficiency disease, or organ transplant history.&#xD;
&#xD;
             16. Virological examination of hepatitis B or hepatitis C during screening meets any&#xD;
             of the following criteria:&#xD;
&#xD;
        a. HBsAg positive and HBV DNA positive (≥1000 copies /mL); b. HCV antibody and HCV-RNA&#xD;
        positive(The result is greater than the detection limit of the analytical method).&#xD;
&#xD;
        17. Major surgery, or unhealed wounds, ulcers or fractures within 4 weeks before&#xD;
        randomization.&#xD;
&#xD;
        18.Has received a live-virus vaccination within 4 weeks before randomization ,allowing&#xD;
        received seasonal flu vaccines without live viruses.&#xD;
&#xD;
        19. Currently participating and receiving study therapy or has participated in a study of&#xD;
        an investigational agent and received study therapy or used an investigational device&#xD;
        within 4 weeks prior to the first dose of study intervention.&#xD;
&#xD;
        20. Investigator judges that the patient is not eligible to join the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ye Guo, doctor</last_name>
    <phone>021-38804518</phone>
    <email>pattrickguo@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai East Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ye Guo, Doctor</last_name>
      <phone>021-38804518</phone>
      <email>pattrickguo@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ye Guo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>February 25, 2019</study_first_submitted>
  <study_first_submitted_qc>February 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2019</study_first_posted>
  <last_update_submitted>October 29, 2019</last_update_submitted>
  <last_update_submitted_qc>October 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

